Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Amarin Gets Bad News from FDA

By Drug Discovery Trends Editor | October 30, 2013

Shares of Amarin Corp. plunged in premarket trading today after an FDA decision cast more doubt on the future of the specialty drugmaker’s lead product.
The Irish company said Tuesday after markets closed that the Food and Drug Administration no longer considers a change in triglyceride levels enough to establish the effectiveness of a drug that aims to reduce the risk of cardiovascular problems like heart attacks in certain patients.
Amarin has developed Vascepa, a prescription-strength form of an omega-3 fatty acid found in fish oil. Regulators approved the drug in 2012 for a relatively narrow use in patients with unusually high triglyceride levels.
The drugmaker has also asked the FDA to allow marketing of the drug for an expanded use in patients with high triglyceride levels and heart disease who are already taking a statin drug to help control their cholesterol.
The FDA told Amarin that clinical research results do not support the hypothesis that a triglyceride-lowering drug significantly reduces the risk for cardiovascular problems in these patients.
A panel of outside advisers to the FDA had already voted earlier this month against recommending the broader use.
Panelists said that while Vascepa significantly lowers fat levels, it is unclear whether that actually translates into fewer heart attacks. The panel members said the FDA should delay a decision on expanding the drug’s use until Amarin completes a study of heart attack rates in patients. Results from that study are not expected until 2015 or 2016.
Amarin shares have plunged since the panel decision was announced. The stock dropped another 16 percent, or 35 cents, to $1.75 Wednesday in premarket trading. That put the share price down about 78 percent since the stock closed 2012 at $8.09.
Date: October 30, 2013
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE